Citations

Clear

2960 citation(s) found for "Kim, P".

IC‐P‐098: The role of APOE‐ɛ4 genotype in early mild cognitive impairment (EMCI): Preliminary results from ADNI‐2
Kim, Sungeun , Ngo, Kwangsik, Petersen, Ronald C. , Aisen, Paul , Jagust, William J. , Weiner, Michael W. , Risacher, Shannon L. , Shen, Li , Foroud, Tatiana , Jack, Clifford R. , Koeppe, Robert A. , Saykin, Andrew J.

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_2 | Pages: No page available

10.1016/j.jalz.2012.05.131 Get It

O4‐01‐01: Classification of MCI and Alzheimer's disease from CSF biomarkers: An ADNI study of Aß, tau and P‐tau versus 83 proteomic analytes
Yan, Jingwen , Shaw, Leslie M. , Trojanowski, John Q. , Aisen, Paul, Petersen, Ronald C. , Weiner, Michael W. , Li, Taiyong , Kim, Sungeun , Swaminathan, Shanker , Risacher, Shannon L. , Saykin, Andrew J. , Shen, Li

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_17 | Pages: No page available

10.1016/j.jalz.2012.05.1634 Get It

P3‐212: Hippocampal subfield atrophy in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort: Relationships to diagnosis and memory impairment
Boddu, Mohan, West, John D. , Wan, Jing , Weiner, Michael W. , Initiative, The Alzheimer's Disease Neuroimaging, Ramanan, Vijay K. , Shen, Li , Risacher, Shannon L. , Kim, Sungeun , Wang, Yang , Crane, Paul K. , Jack, Clifford R. , Saykin, Andrew J. , Initiative, The Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_14 | Pages: No page available

10.1016/j.jalz.2012.05.1434 Get It

Abstract 3994: Loss of miR-23b enhances Pyk2-induced glioma cell migration and invasion
Paquette, Kimberly , Ross, Julianna T.D., Kloss, Jean , Paulino, Vincent M., Loftus, Joseph C. , Tran, Nhan L. , Nasser, Sara A. , Yang, Zhongbo , Kim, Seungchan , Tran, Nhan L

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 3994-3994

10.1158/1538-7445.am2011-3994 Get It

Abstract Glioblastoma is the most common and lethal type of primary brain tumor. Despite recent therapeutic advances in other cancers, the treatment of glioblastomas remains ineffective and essentially palliative due the highly invasive nature of the disease. To discern molecular mechanisms that drive GBM migration, we investigated the potential role of differential expression of microRNAs (miRNA) by comparing the matched large-scale, genome-wide miRNA expression profiles of migrating and migration-restricted human glioma cells. Using a radial migration assay, migrating and non-migrating populations from seven well-established glioma cell lines were isolated and utilized for miRNA expression analysis. Statistical analyses revealed 22 miRNAs common to all seven glioma cell lines were down-regulated in the migrating cell population (p < 0.0005) relative to cells in the non-migratory population. Specifically, we report here that the expression level of miR-23b was markedly down-regulated in migrating glioma cells as compared to migration-restricted cells. Over-expression of miR-23b significantly inhibited glioma cell migration and invasion. A bioinformatics search revealed a conserved target site within the 3’untranslated region (UTR) of Pyk2, a non-receptor tyrosine kinase that has been previously implicated in the regulation of glioma cell migration and invasion. Increased expression of miR-23b reduced the expression level of Pyk2 in glioma cells indicating that miR-23b targets Pyk2. Notably, increased expression of miR-23b did not alter the expression level of the related focal adhesion kinase FAK indicating that miR-23b specifically inhibits the expression Pyk2. Taken together, our study demonstrates that reduced expression of miR-23b facilitates the enhancement of glioma cell migration and invasion via modulation of Pyk2 expression. Thus, these data suggest that certain miRNAs may regulate glioma migration and invasion to influence the progression of this disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3994. doi:10.1158/1538-7445.AM2011-3994
Abstract 1183: miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines
Henry, Jon C., Jiang, Jinmai , Kim, Ji Hye , Roberts, Lewis R. , Nagorney, David M. , Banerjee, Soma , Schmittgen, Thomas D. , Park, Jong Kook , Roberts, Lewis R

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 8_Supplement | Pages: 1183-1183

10.1158/1538-7445.am2011-1183 Get It

Abstract Previous work by us and others reported decreased expression of miR-199a-3p in hepatocellular carcinoma (HCC) tissues compared to adjacent benign tissue. We report here a significant reduction of miR-199a-3p expression in 7 HCC cell lines (Huh7, HepG2, SNU182, PLC/PRF/5, Hep3B, SNU423 and SNU449) compared to primary hepatocytes. To determine if miR-199a-3p has a tumor suppressive role, miR-199a-3p mimetic was transfected into the 7 HCC cell lines. miR-199a-3p mimetic reduced cell proliferation by approximately 60% compared to control oligonucleotide in only two cell lines (SNU449 and SNU423); the proliferation of the other 5 treated cell lines was similar to control oligonucleotide. A miR-199a-3p mimetic formulated with chemical modifications to enhance stability while preserving processing reduced cell proliferation in SNU449 and SNU423 to the same extent as the commercially available miR-199a-3p mimetic. Furthermore, only the duplex miR-199a-3p mimetic, and not the guide strand alone, was effective at reducing cell viability. Since a CD44 variant was essential for c-Met signaling (Orian-Rousseau, et al., Genes Dev. 2002) and c-Met is a known miR-199a-3p target, we hypothesized that miR-199a-3p may also target CD44. Indeed, miRNA target algorithms predict miR-199a-3p to be a putative target of CD44. Immunoblotting confirmed that only the HCC lines that were sensitive to the effects of miR-199a-3p mimetic (SNU449 and SNU423) were CD44+. Direct targeting of CD44 by miR-199a-3p was confirmed using luciferase reporter assays and immunoblotting. Transfection of miR-199a-3p into SNU449 cells reduced in vitro invasion and sensitized the cells to doxorubicin; both effects were enhanced when hyaluronic acid was added to the cell cultures. An inverse correlation between the expression of miR-199a-3p and CD44 protein was noted in primary HCC tissue specimens. The anti-proliferative and anti-invasive properties of miR-199a-3p mimetic on CD44+ HCC may be a useful targeted therapy for CD44+ HCC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1183. doi:10.1158/1538-7445.AM2011-1183
OT2-05-06: ACOSOG Z11101/ACRIN 6694: Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer.
Bedrosian, I., Suman, VJ, Yao, Katharine , Shih, YCT, Yen, TWF, Comstock, Chris, Newstead, Gillian M. , Birdwell, Robyn L. , Kim, E, L'Heureux, DZ, Gatsonis, Constantine

Mayo Clinic

Cancer Research | June 27, 2012 | Volume: 71 | Issue: 24_Supplement | Pages: OT2-05-06-OT2-05-06

10.1158/0008-5472.sabcs11-ot2-05-06 Get It

Abstract Background Surgical planning and local-regional treatment of breast cancer relies on accurate assessment of disease extent including the primary tumor size and the presence/absence of multiple tumor foci. As a staging modality for breast cancer, MRI has shown high sensitivity for detection of additional foci of diseases within the index breast. However, the impact of preoperative breast MRI on reducing re-excision rates and improving local control is less clear. Data from the COMICE trial in the UK suggested that routine use of pre-operative breast MRI did not alter rates of re-excision; however issues have been raised about the lack of quality standards for the MR imaging that may have resulted in the negative results of this trial. Retrospective data suggest that local recurrence is not impacted by use of breast MRI. In concert with data showing no improvement in clinical outcomes of breast cancer patients, concerns have been raised that routine use of preoperative breast MRI is associated with increased rates of mastectomy and delays to surgery. Therefore, the application of MRI for preoperative surgical staging remains controversial. In order to address this ongoing controversy, a joint effort has been launched by ACOSOG and ACRIN for a prospective clinical trial focused on evaluating the impact of preoperative breast MRI on clinically relevant patient outcomes. An important part of this collaboration is implementation of standards of how MRI findings should be clinically managed and used to direct localization methods and surgical planning, thereby creating guidelines for subsequent patient intervention. Trial design/eligibility criteria: A prospective multicenter trial will include women eligible for BCT by standard criteria and randomized between current standard of care, clinical examination and mammography (+/− ultrasound) and the same plus preoperative breast MRI. The study will focus on women at the highest risk of local recurrence: ER/PR/HER-2 negative (triple negative) and HER-2 amplified breast cancers. Specific aims: To compare the rates of local recurrence following breast conserving therapy in a cohort randomized to preoperative staging with mammography or mammography plus breast MRI. Additionally, a comparison of rates of re-operation, time to local recurrence, survival outcomes, contralateral breast cancer rates, rates of multicentric disease and other secondary aims will be performed. Costs and quality of life measures will also be investigated. Statistical methods: A stratified logrank test and Cox partial likelihood score test will be used to assess whether the distribution of LR times differs with respect to diagnostic work-up approach having adjusted for tumor stage. Cox modeling with the Cox partial likelihood score test will be used to examine the strength of association between these time to event distributions and such additional potential prognostic factors as menopausal status, chemotherapy, radiation therapy, ER, PR, number of positive lymph nodes, HER-2/neu expression, Nottingham grade, and Ki-67 expression. Target Accrual: 556 patients Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT2-05-06.
Abstract A30: Integrated analysis of genomic data and annotations in cancer research
Ustach, Carolyn V., Han, Haiyong , Barret, Michael, Keats, Johnathan J., Hoff, Daniel D. Von , Kingsley, Christopher , Kim, Seungchan , Hostetter, Galen H. , Diep, Caroline H. , Hidalgo, Manuel

Mayo Clinic

Molecular Cancer Therapeutics | June 27, 2012 | Volume: 8 | Issue: 12_Supplement | Pages: A30-A30

10.1158/1535-7163.targ-09-a30 Get It

Abstract Many cancer researchers are currently generating heterogeneous genomic data sets containing mRNA expression, array based comparative genomic hybridization (aCGH), and other information from multiple patients. In the near future, data sets will likely include proteomics, methylomics, and high throughput sequencing data. Analytical tools that integrate these different data types to prioritize genes for further study have lagged, however. With this in mind, we have implemented a standalone software application that integrates CGH and mRNA expression profiling data. This application implements several different methods to generate ranked lists of genes and genomic regions based on breakpoint frequency, aberration frequency, and the impact of copy number changes on mRNA expression. The software is Java GUI based, with abstracted object models that can be extended as new genomic data types and annotations become available. We used this application to analyze aCGH datasets generated from 22 primary pancreatic tumor xenografts and mRNA expression datasets from 16 of the 22 samples. Genes which were located near a putative breakpoint and whose expression levels were high in a majority of the xenografts samples were considered putative targets. Preliminary IHC analysis of pancreas primary tumor tissue microarrays confirms one of these putative targets, Chemokine (CXC motif) Ligand 5 (CXCL5). By allowing cancer researchers to correlate genomic aberrations with expression data, we believe that this application will generate more meaningful targets for further biomarker identification and/or drug target discovery. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A30.
Abstract A86: Interaction of nitrate and folate on the risk of breast cancer among postmenopausal women
Inoue‐Choi, Maki , Weyer, Peter J., Anderson, Kristin E. , Ward, Mary H. , Cerhan, James R. , Robien, Kim

Mayo Clinic

Cancer Prevention Research | June 27, 2012 | Volume: 4 | Issue: 10_Supplement | Pages: A86-A86

10.1158/1940-6207.prev-11-a86 Get It

Abstract Background: Ingested nitrate can form N-nitroso compounds endogenously, which may lead to DNA adducts and activating mutations in oncogenes. However, previous studies have reported null or inverse associations between dietary nitrate intake and cancer risk, while nitrate intake from drinking water has shown null or positive associations with cancer risk. These associations may be confounded by protective effects of dietary folate, which provides methyl groups for nucleotide synthesis, and thus plays a vital role in the DNA repair system. In a small case-control study, an increased risk of breast cancer was observed among individuals with high dietary nitrate relative to folate intake. We therefore evaluated interaction of total folate with nitrate intake from diet and drinking water on breast cancer risk in the Iowa Women's Health Study (IWHS). Methods: The IWHS is a prospective cohort study of cancer among 41,836 women in Iowa, initiated in 1986. Dietary intake was assessed at study baseline using a food frequency questionnaire (FFQ). Nitrate intake from foods and total folate intake from foods and dietary supplements were computed using consumption frequencies collected by the FFQ. Nitrate intake from drinking water was assessed using a historical analytical database on Iowa municipal water supplies in 15,151 women using municipal water supply. We evaluated the interaction of nitrate and total folate intake with breast cancer risk using Cox proportional hazard regression modeling, adjusting for potential confounders (age, body mass index, waist-hip-ratio, education, smoking, family history of breast cancer, age at menopause, age at first live birth, estrogen use, total energy intake, and intake of vitamin C and E and flavonoids). Results: After baseline exclusions (history of cancer at baseline, previous mastectomy or partial breast resection, implausible energy intake, or ≥30 missing responses on the FFQ), there were 34,388 postmenopausal women in the analytic cohort. Through 2008, 2,875 incident breast cancer cases were identified. Nitrate intake from diet or drinking water was not associated with breast cancer risk. After stratification by total folate intake, high dietary nitrate intake (>106.1 mg/day) was associated with a marginally decreased risk of breast cancer compared to those with low nitrate intake (≤106.1 mg/day) (HR=0.90, 95% confidence interval=0.81–1.00) only among women with folate intake <400 μg/day (p for interaction = 0.65). There was no interaction of nitrate intake from drinking water and total folate intake on breast cancer risk. Conclusions: Our findings do not support the previously reported increased risk of breast cancer risk among individuals with high dietary nitrate and low folate intake. The inverse association between nitrate intake and breast cancer risk observed among women with low folate intake in the present study may be attributed to residual confounding due to high correlation among intakes of nitrate, folate and antioxidants. Citation Information: Cancer Prev Res 2011;4(10 Suppl):A86.
The Impact of Squamous and Glandular Differentiation on Survival After Radical Cystectomy for Urothelial Carcinoma
Kim, Simon P. , Frank, Igor, Cheville, John C. , Thompson, R. Houston, Weight, Christopher , Thapa, Prabin , Boorjian, Stephen A.

Mayo Clinic

Journal of Urology | June 14, 2012 | Volume: 188 | Issue: 2 | Pages: 405-409

10.1016/j.juro.2012.04.020 | PMID 22704101 Get It

Reduced production of cGMP underlies the loss of endothelium-dependent relaxations in the canine basilar artery after subarachnoid hemorrhage.
Kim, P, Schini, V B, Sundt, Thoralf M. , Vanhoutte, P M

Mayo Clinic

Circulation Research | June 12, 2012 | Volume: 70 | Issue: 2 | Pages: 248-256

10.1161/01.res.70.2.248 | PMID 1310445 Get It

Endothelium-dependent relaxations are inhibited during chronic vasospasm after subarachnoid hemorrhage in the canine basilar artery, although the luminal release of endothelium-derived relaxing factor (EDRF) is maintained. The present study investigated the mechanisms underlying the impaired vascular reactivity and in particular whether the loss of responsiveness of the smooth muscle to EDRF is due to an impaired production of cGMP. Bradykinin and nitric oxide evoked concentration-dependent relaxations in isolated canine basilar arteries with and without endothelium, respectively, which were reduced in the subarachnoid hemorrhage group. Relaxations evoked by M&B22,948 (an inhibitor of cGMP phosphodiesterases) were smaller, but those evoked by the lipophilic cGMP analogue 8-bromo-cGMP were potentiated slightly in the subarachnoid hemorrhage group. The resting levels of cGMP in rings with endothelium (reflecting the effect of spontaneous release of EDRF) and those evoked by bradykinin in rings with endothelium and by nitric oxide in rings without endothelium were diminished in the subarachnoid hemorrhage group. These data indicate that the altered endothelium-mediated relaxations of the smooth muscle after subarachnoid hemorrhage is due, at least in part, to an impaired activation of soluble guanylate cyclase leading to a reduced production of cGMP in the smooth muscle.